Dec 09 2024 25 mins 3
Dr. Eric Klein, Distinguished Scientist at GRAIL, provides a research update from GRAIL’s 2024 findings on multi-cancer early detection (MCED) testing, presented at ASCO, ESMO, AACR and more. He explores insights from the first real-world evaluation of repeat multi-cancer early detection testing, data on how multi-cancer early detection (MCED) testing is helping cancer survivors by detecting recurrence and new cancers, and findings on using MCED to detect high grade, clinically significant prostate cancer over indolent cases. Plus, the economic and emotional impacts of cancer screening, and three insightful case studies.
Watch the full episode on YouTube: https://youtu.be/QU6s3P1B5Bo
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.
Rx only. See Important Safety Information: https://www.galleri.com/safety-information
Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
